SOBI, INC
WALTHAM, MA

Swedish Orphan Biovitrum AB, better known as Sobi, is a well-regarded international biopharmaceutical firm based in Stockholm, Sweden. As a public limited liability company on Nasdaq Stockholm, Sobi is dedicated to crafting innovative treatments for rare diseases. It boasts operations across 25 countries and delivers its therapies globally to over 60 nations. Sobi primarily operates through two main lines: Haemophilia and Specialty Care. In the haemophilia market, it aims to be a frontrunner in Europe, the Middle East, and Africa. The Specialty Care division focuses on a range of rare diseases and specialty indications, benefiting from Sobi's deep expertise in niche markets. Research and development efforts at Sobi target crucial areas like haemophilia, inflammation, genetic disorders, and metabolic diseases. By employing an integrated biotechnology strategy, Sobi efficiently manages its value chain, from research to patient access and distribution. This holistic method enhances its ability to foster early-stage drug development partnerships while delivering proprietary treatments. Governed by the Swedish Corporate Governance Code with a 'comply or explain' approach, Sobi holds its Annual General Meeting each year in the first half of the year. During these meetings, important topics such as board elections, auditor appointments, director remuneration, and strategies for business growth are discussed. Sobi is incorporated under Florida state law, with a registered office located at 890 Winter Street, Suite 115, Waltham, MA. Although it has its primary operations in Sweden, the company holds a significant presence spanning numerous global territories. The Board of Sobi includes esteemed members like Cameron McDonough (Director), Rami Levin (President), and Nils Fredrik Berg (Secretary). They steer the organization toward achieving strategic goals aimed at advancing healthcare solutions for underserved patients worldwide. For more information, you can visit their website at sobi.com.